Sector: Health Care.Industry: Biotechnology
Viracta Therapeutics Inc is a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma.
Earnings
see more| Q1 2021 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2021-05-02 | ||||||
| REV | |||||||
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| VIRX | Viracta Therapeutics | 0% |
Viracta Therapeutics Company Questions & Answers
Q
How do I buy Viracta Therapeutics (VIRX) stock?
A
You can purchase shares of Viracta Therapeutics (NASDAQ: VIRX) through any online brokerage.
Q
Who are Viracta Therapeutics's (VIRX) main competitors?
A
Other companies in Viracta Therapeutics’s space includes: Neurocrine Biosciences (NASDAQ:NBIX), CureVac (NASDAQ:CVAC) and Amgen (NASDAQ:AMGN).
Q
What is the target price for Viracta Therapeutics?
A
The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by Evercore ISI Group on 2021-03-25. The analyst firm set a price target for 45.00 expecting VIRX to rise to within 12 months (a possible 471.07% upside). 1 analyst firms have reported ratings in the last year.
Q
How much is Viracta Therapeutics (VIRX) stock ?
A
The stock price for Viracta Therapeutics (NASDAQ: VIRX) is $7.88 last updated Today at 8:00:02 PM.
Q
When is the next Viracta Therapeutics (VIRX) dividend?
A
There are no upcoming dividends for Viracta Therapeutics.
Q
When is Viracta Therapeutics (NASDAQ:VIRX) reporting earnings?
A
Viracta Therapeutics’s Q1 earnings are confirmed from now on May 2, 2021.
Q
When is the upcoming split for VIRX?
A
There is no upcoming split for Viracta Therapeutics.